RemeGen Co., Ltd. (HKG:9995)
Hong Kong
· Delayed Price · Currency is HKD 39.95
+2.50 (6.68%)
May 13, 2025, 2:45 PM HKT
RemeGen Revenue
RemeGen had revenue of 525.97M CNY in the quarter ending March 31, 2025, with 59.17% growth. This brings the company's revenue in the last twelve months to 1.91B, up 53.59% year-over-year. In the year 2024, RemeGen had annual revenue of 1.72B with 58.54% growth.
Revenue (ttm)
1.91B CNY
Revenue Growth
+53.59%
P/S Ratio
11.84
Revenue / Employee
637.68K CNY
Employees
2,999
Market Cap
24.27B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeiGene | 32.49B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| JD Health International | 61.89B |
| WuXi Biologics | 19.87B |
| Innovent Biologics | 10.03B |
| Alibaba Health Information Technology | 31.39B |
| Akeso | 2.26B |
| Sichuan Kelun-Biotech Biopharmaceutical | 2.06B |